Detail akcie Novavax Rg online

Business Summary: Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Novavax Inc revenues decreased 31% to $682.2M. Net loss decreased 66% to $187.5M. Revenues reflect Grants decrease from $427.3M to $0K, Product Sales decrease of 64% to $190.2M. Lower net loss reflects Biotechnology segment loss decrease of 56% to $248.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$5.41 to -$1.23.